H.R. 3452 (107th): Best Pharmaceuticals for Children Act

Introduced:
Dec 11, 2001 (107th Congress, 2001–2002)
Status:
Died (Referred to Committee) in a previous session of Congress
See Instead:

S. 1789 (same title)
Signed by the President — Jan 04, 2002

This bill was introduced on December 11, 2001, in a previous session of Congress, but was not enacted.

Introduced
Dec 11, 2001
 
Sponsor
James “Jim” Greenwood
Representative for Pennsylvania's 8th congressional district
Party
Republican
Text
Read Text »
Last Updated
Dec 11, 2001
Length
46 pages
Related Bills
S. 1789 (identical)

Signed by the President
Jan 04, 2002

 
Full Title

To amend the Federal Food, Drug, and Cosmetic Act to improve the safety and efficacy of pharmaceuticals for children.

Summary

No summaries available.

 
Cosponsors
1 cosponsors (1D) (show)
Committees

House Energy and Commerce

Health

The committee chair determines whether a bill will move past the committee stage.

 
Primary Source

THOMAS.gov (The Library of Congress)

GovTrack gets most information from THOMAS, which is updated generally one day after events occur. Activity since the last update may not be reflected here. Data comes via the congress project.

Widget

Get a bill status widget for your website »

Citation

Click a format for a citation suggestion:

Notes

H.R. stands for House of Representatives bill.

A bill must be passed by both the House and Senate in identical form and then be signed by the president to become law.

The bill’s title was written by its sponsor.

GovTrack’s Bill Summary

We don’t have a summary available yet.

Library of Congress Summary

The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress.


12/11/2001--Introduced.
Best Pharmaceuticals for Children Act - Amends the Public Health Service Act to direct the Secretary of Health and Human Services, through the National Institutes of Health, to develop an annual list of approved drugs for which:
(1) there is an approved or pending new drug application or no patent or market exclusivity protection; and
(2) additional pediatric safety and effectiveness studies are needed.
Directs the Secretary to award contracts to entities with appropriate experience for pediatric clinical trials of such drugs.Establishes a Food and Drug Administration (FDA) contract process for related labeling changes.Amends the Federal Food, Drug, and Cosmetic Act to:
(1) eliminate the user fee waiver for pediatric supplements to a human drug application;
(2) provide priority status for pediatric supplements;
(3) include neonates within the definition of pediatric studies;
(4) provide for dissemination of pediatric supplement information; and
(5) set forth requirements for the additional six-month exclusivity period for new or already-marketed pediatric drugs.Directs the Secretary to establish an Office of Pediatric Therapeutics within the Office of the Commissioner of Food and Drugs, which shall coordinate all FDA pediatric activities.Includes within the purposes and activities of the Foundation for the National Institutes of Health the collection of funds for pediatric pharmacological research.Directs the Secretary to contract with the Institute of Medicine to review Federal regulations, reports, and support for research involving children, with particular attention to issues of compensation, informed consent, and risk/ benefits assessments in terms of research versus therapeutic treatment.

House Republican Conference Summary

The summary below was written by the House Republican Conference, which is the caucus of Republicans in the House of Representatives.


No summary available.

House Democratic Caucus Summary

The House Democratic Caucus does not provide summaries of bills.

So, yes, we display the House Republican Conference’s summaries when available even if we do not have a Democratic summary available. That’s because we feel it is better to give you as much information as possible, even if we cannot provide every viewpoint.

We’ll be looking for a source of summaries from the other side in the meanwhile.

Use the comment space below for discussion of the merits of H.R. 3452 (107th) with other GovTrack users.
Your comments are not read by Congressional staff.

comments powered by Disqus